Table 3

HRs and 95% CIs, number of persons, events and person-years, comparing tumour necrosis factor inhibitor (TNFi) versus biologics-naive rheumatoid arthritis (RA) for each outcome

Outcome0–2 years2–5 years5+ yearsOverall
CIN 1
 HR*1.77 (1.14 to 2.73)1.05 (0.61 to 1.79)0.74 (0.37 to 1.49)1.23 (0.87 to 1.74)
 N events, TNFi2716952
 N patients, TNFi8943741850078943
 Pyr, TNFi16 47418 60919 49954 581
CIN 2+
 HR*1.55 (1.04 to 2.32)1.39 (0.92 to 2.10)1.06 (0.63 to 1.78)1.36 (1.01 to 1.82)
 N events, TNFi30281775
 N patients, TNFi9018749350669018
 Pyr, TNFi16 62918 80819 70755 144
Invasive cervical cancer
 HR*3.22 (1.37 to 7.58)2.10 (1.04 to 4.23)
 N events, TNFi42814
 N patients, TNFi9629802154499629
 Pyr, TNFi17 77420 16621 25159 191
  • Stratified by time since start of follow-up (<2 years, 2–5 years, 5+ years).

  • *Stratified on decade of birth and adjusted for educational level, number of cervical screens past five years, comorbidities, marital status and total days spent in hospital during last five years, also implicitly adjusted for age since age was used as the model's timescale.

  • †Not computed due to low number of events.

  • CIN, cervical intraepithelial neoplasia.